CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06685718
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:54.727123+00:00
- Published At
- 2026-04-15T00:00:00+00:00
- Record Updated At
- 2026-04-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Non-Small Cell Lung Cancer", "Lung Cancer", "NSCLC", "NSCLC (Non-small Cell Lung Carcinoma)", "EGFR Activating Mutation", "EGFR Mutation-Related Tumors"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-15"- protocolSection.identificationModule.nctId
"NCT06685718"- protocolSection.identificationModule.officialTitle
"Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.